Stugeron, tablets 25 mg 50 pcs

Pharmacodynamics

A class IV selective calcium channel blocker. Improves cerebral, coronary and peripheral blood circulation; improves microcirculation.

Inhibiting entry of calcium ions into vascular smooth muscle cells, reduces smooth muscle tone of arterioles, decreases their sensitivity to biogenic vasoconstrictors (adrenaline, noradrenaline), bradykinin. It reduces the excitability of the vestibular apparatus. It is characterized by high tropism to the cerebral vessels. It improves microcirculation by increasing red blood cell deformability and decreasing high blood viscosity. It has moderate antihistamine activity.

Pharmacokinetics

Intake

After oral administration the C max of cinnarizine in plasma is noted after 1-3 hours.

Distribution

The binding to plasma proteins is 91%.

Metabolism

Cinnarizine is completely metabolized.

Elimination

The T 1/2 is 4 hrs. It is excreted as metabolites: 1/3 by the kidneys, 2/3 – through the intestine.

< br>.

Indications

• Treatment and prevention of cerebral circulatory disorders: Cerebral atherosclerosis, conditions after strokes, craniocerebral injuries, discirculatory encephalopathy;
• labyrinth disorders (for supportive therapy for dizziness, tinnitus, nystagmus, nausea, vomiting);
• prevention of kinetosis;
• prevention of migraine;
• treatment and prevention of peripheral circulatory disorders: Raynaud’s disease and syndrome; acrocyanosis, intermittent claudication, trophic disorders, trophic and varicose ulcers, diabetic angiopathy, paresthesias, microcirculatory disorders;
• in the complex therapy in the following cases: rapid mental fatigue, irritability, decreased mood, memory and concentration disorders.

.

Active ingredient

Cinnarizin

Composition

1 tablet contains:

Active substances:

Cinnarizine – 25 mg.

Auxiliary substances:

colloidal silicon dioxide,

potato starch,

magnesium stearate, <

povidone,

talk,

corn starch,

lactose monohydrate.

How to take, the dosage

Set on an individual basis. The optimal therapeutic dose should be gradually moved to the optimal dose. The maximum daily dose is 225 mg (9 tablets).

The drug should be taken after meals.

Children aged 6-12 years are prescribed half the adult dose.

In cerebrovascular disorders

Adults are prescribed 25-50 mg 3 times a day.

In peripheral circulation disorders

Prescribe 50-75 mg 3 times/day.

In labyrinth disorders

Prescribe 25 mg 3 times/day.

For prevention of kinetosis

Adults are prescribed 25 mg 30 minutes before travel with a repeat dose every 6 hours.

Interaction

When Stuggeron is used together with ethanol (or ethanol-containing drugs), hypotensive, nootropic and vasodilators, other drugs that have a depressing effect on the CNS (tricyclic antidepressants, sleeping pills, sedatives) their action is increased.

.

Special Instructions

In Parkinson’s disease Stuggeron is prescribed only in exceptional cases when the expected benefit significantly exceeds the potential risk.

Stuggeron, due to the presence of an antihistamine effect, may negate the positive reactions in skin diagnostic tests. In this regard, the drug should be discontinued 4 days before the tests.

Patients taking the drug should not drink alcohol.

Control of laboratory parameters

In long-term use of Stuggeron, monitoring of laboratory blood parameters and parameters of liver and kidney function is recommended.

Impact on ability to drive vehicles and other mechanisms requiring increased concentration

Patients taking the drug should be cautious when engaged in activities requiring increased attention and rapid psychomotor reactions.

.

Contraindications

Hypersensitivity to the drug. Erythematous lupus.

.

Side effects

Digestive system: dyspepsia, dry mouth; in single cases – cholestatic jaundice.

CNS disorders: rarely headache; in elderly patients with prolonged use of Stuggeron extrapyramidal syndromes and depression are possible (in these cases the treatment should be stopped).

Others: allergic reactions, weight gain, increased sweating; in single cases – lupus-like syndrome, ruber lichen planus.

.

Overdose

Symptoms: vomiting, drowsiness, tremor, arterial hypotension, coma.

Treatment: gastric lavage, administration of activated charcoal; symptomatic therapy is carried out. There is no specific antidote.

Pregnancy use

While no teratogenic effect of Stugeron was found in animal studies, the use of the drug in pregnancy is possible only in exceptional cases when the expected benefit to the mother significantly exceeds the potential risk to the fetus.

It is not known whether cinnarizine is excreted with the breast milk, so the use of Stuggeron during lactation (breastfeeding) is not recommended.

.

Similarities

Cinnarizin, Cinnarizin Renewal